{"analyses":[{"ciLowerLimit":"0.57","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.95","groupDescription":"Stratified Analysis: The stratification factors were ECOG PS at randomization (0 vs. 1); LDH at randomization (\\<=ULN vs \\>ULN) via local laboratory test; Presence of liver metastases at enrollment (yes vs. no); Prior receipt of PCI (yes vs. no).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"= 0.0174","paramType":"Hazard Ratio (HR)","paramValue":"0.73","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.49","spread":"9.49","upperLimit":"12.16","value":"10.64"},{"groupId":"OG001","lowerLimit":"11.89","spread":"11.89","upperLimit":"16.36","value":"13.24"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"242"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to the date of death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received atezolizumab, 1200 mg, Q3W as IV infusion on Day 1 of each 21-day cycle until unacceptable toxicity or PD whichever occurred first.","id":"OG000","title":"Atezolizumab"},{"description":"Participants received atezolizumab, 1200 mg, Q3W as IV infusion and lurbinectedin, 3.2 mg/m\\^2, Q3W as IV infusion on Day 1 of each 21-day cycle until unacceptable toxicity or PD whichever occurred first.","id":"OG001","title":"Atezolizumab+ Lurbinectedin"}],"paramType":"MEDIAN","populationDescription":"FAS included all participants randomized into the randomized phase, regardless of whether or not the assigned study treatment was received.","reportingStatus":"POSTED","timeFrame":"Up to 26 months","title":"Randomized Phase: Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}